The Scott of Pot At It Again.. Cann Group aiming for over-the-counter CBD approval in late 2022

We presume the angle is getting liberal party members to give approval and buy stock at the same time so they can all get rich selling placebo CBD to all those idiots who refuse to get vaccinated for COVID.

Here’s the mindless blurb

Phase I clinical trial of the Satipharm CBD capsules in which results demonstrated the safety and high performance of the oral capsule technology, including the superior delivery profile of cannabidiol (CBD) compound to trial subjects. Phase II clinical trial of the Satipharm CBD capsules showed significantly reduced monthly seizure frequency in the treatment of children suffering from refractory, or treatment-resistant epilepsy when the Satipharm capsules were added to current medications. The treatment was generally well tolerated and the median reduction in seizures was 81.9% following 12 weeks of treatment.

We’ll let Pondering Pot tell you what the angle is

Cann Group (ASX: CAN) aiming for over-the-counter CBD approval in late 2022

Primary Sponsor

 


Karma Koala Podcast

Top Marijuana Blog